Deals, pipeline readouts and company news from across biotech and pharma.
The company reported third-quarter net revenue of $180.3M and lifted its full-year total revenue outlook, while the FDA approved an oral pellet formulation of ORLADEYO for hereditary angioedema.
The Nasdaq-listed calibration and test-measurement firm raised its full-year service growth outlook and flagged an August acquisition that extends its hospital biomedical reach.
With cash of $1.0m covering operations only into mid-November, InMed says its proposed Mentari Therapeutics merger should cure a Nasdaq equity shortfall; shareholders vote on 4 November.
The specialty ingredients maker reported Adjusted EBITDA of $121 million for the quarter to 30 September 2026 and issued fiscal 2027 guidance, despite a GAAP net loss.
The EEG-based point-of-care company reported a 90% gross margin, launched its delirium monitoring solution in full and won two FDA 510(k) clearances.
The US drugmaker reaffirmed its 2026 guidance and reported $285M in cash and investments, with Phase 3 ACCEL data for tenapanor in chronic idiopathic constipation due in the second half of 2027.
Profound Medical has agreed to supply TULSA-PRO to Cook Medical's iMRI Division for US sales through the Copernicus program, while keeping its own direct sales team.
Growth in Repatha, Evenity, Uplizna, Imdelltra and Tezspire offset sharp declines in Prolia and Xgeva, while Amgen says it continues to engage the FDA on Tavneos.
After FDA approvals for GENGLYCOS and FAYUVI, Ultragenyx is restructuring, ending two programmes and reaffirming a target of profitability in 2027.
The US company also seeks EU re-examination of arimoclomol and plans a paediatric sNDA for infants under 24 months in the first quarter of 2027.
Corcept Therapeutics reports third-quarter net income of $126.8m and flags a CHMP positive opinion for relacorilant in ovarian cancer and a December US decision date in Cushing's syndrome.
The cardiac surgery device maker reported net income of $4.1 million for the quarter and issued full-year 2026 revenue guidance of about $606–610 million.
The US rare-disease drugmaker reported Q3 net product sales of $185.7 million and flagged several regulatory submissions planned for the first half of 2027.
Alkermes reported higher third-quarter 2026 revenue on LUMRYZ sales after the Avadel transaction, while GAAP net income was $16.3 million, and it left its 2026 financial expectations unchanged.
Revvity reported Q3 revenue of $729 million, with Life Sciences outpacing Diagnostics, and raised its full-year pro forma outlook while a China immunodiagnostics sale remains pending.
The gene-editing company's third-quarter update points to a potential US filing in sickle cell disease and completed BEAM-302 pivotal dosing in H1 2027.
The US generics and specialty drugmaker swung to a GAAP net loss on Kashiv-related costs, while lifting revenue, adjusted EBITDA and adjusted EPS targets but trimming its cash flow outlook.
Rhythm Pharmaceuticals reports 29% quarterly growth for IMCIVREE after its US hypothalamic obesity launch, alongside a cheaper bivamelagon licence deal and a new term loan.
Pfizer reported Q3 revenues of $16.6 billion and lifted full-year revenue and adjusted EPS guidance, while booking a $650 million charge for its Innovent Biologics in-licensing deal.
Teva's generic lenalidomide sales fell in the US, but AUSTEDO, AJOVY and UZEDY grew a combined 33% and all three received raised 2026 outlooks.
Karyopharm Therapeutics and affiliate KPT Texas LLC have begun soliciting votes on a prepackaged Chapter 11 plan, with every voting creditor class signed up to a restructuring support agreement.
The space and defence group reported a $55.7M net loss and a $742M backlog, and its only life-sciences item is new ISS biopharmaceutical research contracts.
The US biodefence and opioid-overdose company reported lower NARCAN, smallpox countermeasure and BAT sales, partly offset by higher CYFENDUS anthrax vaccine revenue.
The spinal and pelvic device maker reported narrower losses and positive adjusted EBITDA, citing a September FDA 510(k) clearance and new October hospital payment categories.
Neurocrine Biosciences reported total revenue of $1.123bn for Q3 2026 and lifted its full-year Ingrezza net sales guidance to $2.9–2.925bn, with Soleno's Vykat XR now contributing.
The lymphedema device maker reported third-quarter revenue of $91.9 million, announced an expanded 510(k) clearance and filed a new 510(k) for Flexitouch Pro.
The Nasdaq-listed medtech reported $6.0 million net income, prepaid $15 million of its term loan and updated 2026 net sales guidance to $590-595 million.
Third-quarter Casgevy revenue rose 30% on the previous quarter, while new paediatric clearances and two FDA RMAT designations marked regulatory progress across the pipeline.
Third-quarter revenue rose 12% to $3.44bn as the Crinetics acquisition completed, CASGEVY gained paediatric approvals and a US decision on povetacicept in IgAN draws near.
BioMarin reported a GAAP net loss of $123m for Q3 2026, revised full-year guidance, and gained FDA and EMA milestones for Voxzogo in hypochondroplasia and achondroplasia.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.